Literature DB >> 1652552

Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus.

M J Francis1, G Z Hastings, F Brown, J McDermed, Y A Lu, J P Tam.   

Abstract

The multiple antigenic peptide (MAP) system for presenting epitopes to the immune system has been studied with an immunogenic foot-and-mouth disease virus (FMDV) peptide comprising amino acids 141-160 of protein VP1. Neutralizing antibody responses known to protect guinea-pigs against challenge infection were obtained with a single inoculation of 0.8-4 micrograms of peptide, presented as an octamer or a tetramer, whereas 20 micrograms of a dimer were required to evoke a similar level of antibody. A monomeric preparation did not elicit measurable levels of neutralizing antibody at doses up to 20 micrograms. The octameric MAP was also immunogenic using an aluminum hydroxide adjuvant. Antibodies elicited by the octameric, tetrameric and dimeric constructs differed qualitatively in their reaction with sequences within the 141-160 peptide. Those against the octamer reacted poorly with peptides within the 141-160 sequence, whereas those elicited by the tetramer and dimer reacted preferentially with the peptides covering the N-terminal region. The levels of neutralizing antibody obtained with the octamer and tetramer compare favourably with those obtained when the FMDV peptide is attached to carrier proteins but are lower than those obtained when it is presented as part of a peptide-hepatitis B virus core particle. Nevertheless, the ability to elicit protective levels of neutralizing antibody without the use of a carrier protein would be a distinct advantage in the development of synthetic peptide vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652552      PMCID: PMC1384538     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

Review 1.  Peptide vaccines for viral diseases.

Authors:  M J Francis
Journal:  Sci Prog       Date:  1990       Impact factor: 2.774

2.  Protection of cattle against foot-and-mouth disease by a synthetic peptide.

Authors:  R DiMarchi; G Brooke; C Gale; V Cracknell; T Doel; N Mowat
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

3.  Peptide vaccines based on enhanced immunogenicity of peptide epitopes presented with T-cell determinants or hepatitis B core protein.

Authors:  M J Francis; B E Clarke
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

4.  Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals.

Authors:  M P Broekhuijsen; J M van Rijn; A J Blom; P H Pouwels; B E Enger-Valk; F Brown; M J Francis
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

5.  Enzyme-immunoassays for antibodies in measles, cytomegalovirus infections and after rubella vaccination.

Authors:  A Voller; D E Bidwell
Journal:  Br J Exp Pathol       Date:  1976-04

6.  Immune response to uncoupled peptides of foot-and-mouth disease virus.

Authors:  M J Francis; C M Fry; D J Rowlands; J L Bittle; R A Houghten; R A Lerner; F Brown
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

7.  Synthetic peptide vaccines against foot-and-mouth disease. II. Comparison of the response of guinea-pigs, rabbits and mice to various formulations.

Authors:  A D Murdin; T R Doel
Journal:  J Biol Stand       Date:  1987-01

8.  Qualitative and quantitative differences in the immune response to foot-and-mouth disease virus antigens and synthetic peptides.

Authors:  M J Francis; C M Fry; D J Rowlands; F Brown
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

9.  The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid).

Authors:  G Fox; N R Parry; P V Barnett; B McGinn; D J Rowlands; F Brown
Journal:  J Gen Virol       Date:  1989-03       Impact factor: 3.891

10.  Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes.

Authors:  J P Tam; Y A Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  16 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  Mapping major and minor T-cell epitopes in vitro and their immunogenic or tolerogenic effect in vivo in non-human primates.

Authors:  P R Walker; R Smerdon; J Haron; T Lehner
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

3.  Major linear antibody epitopes and capsid proteins differentially induce protective immunity against Theiler's virus-induced demyelinating disease.

Authors:  H Yahikozawa; A Inoue; C S Koh; Y K Choe; B S Kim
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.

Authors:  D Chargelegue; O E Obeid; S C Hsu; M D Shaw; A N Denbury; G Taylor; M W Steward
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Presentation of T-cell epitopes assembled as multiple-antigen peptides to murine and human T lymphocytes.

Authors:  D Grillot; D Valmori; P H Lambert; G Corradin; G Del Giudice
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

6.  How well can a T-cell epitope replace its parent carrier protein? A dose-response study.

Authors:  James S Cavenaugh; Hsu-Kun Wang; Cory Hansen; Richard S Smith; James N Herron
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

7.  Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.

Authors:  Y T Chen; E Stockert; Y Chen; P Garin-Chesa; W J Rettig; P van der Bruggen; T Boon; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

8.  Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Authors:  Assefa Wondimu; Tianqian Zhang; Thomas Kieber-Emmons; Phyllis Gimotty; Katrin Sproesser; Rajasekharan Somasundaram; Soldano Ferrone; Chun-Yen Tsao; Dorothee Herlyn
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

Review 9.  Need for cellular and humoral immune responses in bovines to ensure protection from foot-and-mouth disease virus (FMDV)--a point of view.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

10.  The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis.

Authors:  C Borner; I Martinou; C Mattmann; M Irmler; E Schaerer; J C Martinou; J Tschopp
Journal:  J Cell Biol       Date:  1994-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.